The ECOG-ACRIN Cancer Research Group and PrECOG, LLC, its associated research company, will be well represented at the 49th annual American Society of Clinical Oncology meeting to be held May 31 – June 4, 2013 in Chicago, Illinois. Investigators associated with the Group will contribute more than 20 research presentations to the meeting, including 6 oral sessions. Topics span ECOG-ACRIN’s three broad scientific programs: Cancer Control and Outcomes, Therapeutic Studies and Biomarker Sciences. The table below provides information about all sessions and publications associated with this meeting, including collaborations with other research groups. Users may save or print the complete listing by selecting the PDF Download option below the table.

Committee(s)StudyTitleLead AuthorAbstract #Session
Type
Date/Time
(Central)
Location
N/AN/AClinical Trials Participation Awards sponsored by the Coalition of Cancer Cooperative Groups(Comis RL)N/AHighlights of the DaySunday, June 2, 8:00-9:30 amE Hall D1
MelanomaECOG E1608Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) vs. Ipi alone in metastatic melanoma: E1608. **Selected by ASCO meeting organizers for additional media attention at the ASCO 2013 Press Briefing**Hodi FSCRA9007 Abstract embargoedOral Saturday, June 1, 3:30-3:45 pmS406
Breast; Developmental Therapeutics; Patient-centered Outcomes and Quality of LifeECOG E5103Biomarker prediction of chemotherapy-related amenorrhea.Ruddy KJ9508OralSunday, June 2, 10:30-10:45 amS100a
BreastPrECOG 0105Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer.Telli ML1003OralMonday, June 3, 10:45-11:00 amN Hall B1
GenitourinaryACRIN 6687Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases correlates with progression-free survival: Preliminary results from ACRIN 6687.Yu EY5003OralSunday, June 2, 8:30-8:45 amE Hall D2
Head and NeckECOG E1308E1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose vs. standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx.Marur S6005OralSunday, June 2, 9:45-10:00 amE354a
Head and NeckECOG E1395 and E3301Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck.Mehra R6006OralSunday, June 2, 10:00-10:15 amE354a
Breast; Developmental Therapeutics; Patient-centered Outcomes and Quality of LifeECOG E5103Does biomarker information impact patients' preferences for therapy?Partridge AH6527 Board 16Poster Discussion with Patricia Ganz, MDSunday, June 2 12:00-12:15 pm (display 8:00am-12:00 pm)S406 (display S405)
Head and NeckECOG E5397Association of the 3'-untranslated region KRAS-variant cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.Weidhaas JB6016 Board 5Poster Discussion with Julie E. Bauman, MD, PhDSaturday, June 1, 5:15-5:30 pm (display 1:15-5:15 pm)E354a (display E450a)
ThoracicECOG E1508Three-arm randomized phase II study of cisplatin and etoposide (CE) vs. CE with either vismodegib (V) or cixutumumumab (Cx) for patients with extensive stage small cell lung cancer (E1508).Belani CP7508 Board 2Poster Discussion with William J. Petty, MDSaturday, June 1, 4:45-5:00 pm (display 1:15-5:15 pm) E Hall D2 (display E450b)
ThoracicACRIN 6654The effects of physician-delivered brief smoking cessation on ACRIN/National Lung Screening Trial (NLST) participants smoking behaviors.Gareen IF7525 Board 19Poster Discussion with Andrea Bezjak, MD, CMSaturday, June 1, 5:15-5:30 pm (display 1:15-5:15 pm) E Hall D2 (display E450b)
Head and NeckECOG E5397Activity of cetuximab in head and neck squamous cell carcinoma patients with PTEN loss or mutation of PIK3CA mutation treated on E5397, a phase III trial of cisplatin with placebo or cetuximab. Burtness BA6028 Board 17Poster Discussion with Julie E. Bauman, MD, PhDSaturday, June 1, 5:15-5:30 pm (display 1:15 - 5:15 pm)E450a (display E354a)
MelanomaECOG E2602Phase II study of graded-dosage peginterferon alpha-2b (PEG-IFN) antiangiogenic therapy in patients with metastatic melanoma overexpressing basic fibroblast growth factor (FGF-2): An Eastern Cooperative Oncology Group study E2602.Go RS9038General PosterSaturday, June 1, 8:00-11:45 am S Hall A2
LeukemiaECOG E1905Application of the French prognostic score (FPS) to assess overall survival in a U.S.-based cohort of patients treated with azacitidine.Zeidan A7126General PosterSunday, June 2, 8:00-11:45 amS Hall A2
ThoracicACRIN 6654Racial differences in perceived risk in participants enrolled in the American College of Radiology (ACRIN-6654) arm of the National Lung Screening Trial (NLST).Lathan C1563General PosterMonday, June 3, 1:15-5:00 pmS Hall A2
ThoracicECOG E2303Predictive biomarkers for response to rituximab in a prospective phase II trial of weekly carboplatin, and cetuximab induction and chemoradiation in patients with resectable stage III/Iva,b head and neck squamous cell carcinoma: Eastern Cooperative Oncology Group E2303.Psyrri A6081General PosterSaturday, June 1, 8:00-11:45 amS Hall A2
ThoracicECOG E4599Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer.Ahn DH8046General PosterSaturday, June 1, 8:00-11:45 amS Hall A2
ThoracicECOG E4508Exploratory biomarker analyses from ECOG E4508: Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, IMC-A12, or both, for advanced non-small cell lung cancer patients.Aggarwal C8106General PosterSaturday, June 1, 8:00-11:45 amS Hall A2
MyelomaECOG E4A03Evaluation of protocol mandated testing in E4A03, a randomized phase III study of CC-5013 plus dexamethasone vs. CC-5013 plus low dose dexamethasone in multiple myeloma.Callander NSInfo to comePublication Only
GastrointestinalECOG E3201Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil and leucovorin vs oxaliplatin, 5-fluorouracil and leucovorin vs 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201- an updated survival analysis. Nimeiri HSe14711Publication Only
Symptom ManagementECOG E2702/ SOAPPLack of patient-clinician concordance across disease and treatment status in cancer.Chandwani KDe20520Publication Only
Breast - collaboration with SWOGSWOG S0221S0221: Comparison of 2 schedules of paclitaxel as adjuvant therapy for breast cancer.Budd GT1008OralMonday, June 3, 12:15-12:30 pmN Hall B1
Breast - collaboration with AllianceCALGB 49907Effect of renal function on outcomes in the adjuvant treatment of older women with breast cancer (> 65 years). An ancillary data study of CALGB/CTSU 49907 (Alliance).Lichtman SM9515 Board 4Poster Discussion with David S. Ettinger, MDSaturday, June 1, 4:45-5:00 pm (display 1:15-5:15 pm)S100a (display S102)
Genitourinary - collaboration with AllianceCALGB 8030325-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer: Findings from CALGB 80303 (Alliance).Van Loon K4022 Board 14Poster Discussion with Albert C. Lockhart, MDMonday, June 3, 4:45-5:00 pm (display 1:15-5:15 pm)E Hall D1 (display E450a)
Genitourinary - collaboration with AllianceCALGB 90206Identification of predictive biomarkers of overall survival in patients with advanced renal cell carcinoma treated with interferon alpha +/- bevacizumab: Results from CALGB 90206 (Alliance).Nixon AB4520 Board 9Poster Discussion with Sumanta K. Pal, MDTuesday, June 4, 11:30-11:45 (display 8:00am-12:00 pm)E354a (display E450b)
Genitourinary and Symptom Management - collaboration with AllianceCALGB 90401A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).Hertz DL11053General PosterMonday, June 3, 1:15-5:00 pmS Hall A2
PDF Icon Download